Results 1 to 10 of about 331,356 (244)

Alternative Complement Pathway Inhibition by Lampalizumab [PDF]

Ophthalmology Science, 2023
Purpose: Lampalizumab, an antigen-binding fragment of a humanized monoclonal antibody directed against complement factor D (CFD), is designed to treat geographic atrophy (GA) secondary to age-related macular degeneration.
Rose Edmonds, MS, Verena Steffen, MSc, Lee A. Honigberg, PhD, Michael C. Chang, PhD   +3 more
doaj   +3 more sources

Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway [PDF]

Frontiers in Immunology, 2021
The complement system is central to first-line defense against invading pathogens. However, excessive complement activation and/or the loss of complement regulation contributes to the development of autoimmune diseases, systemic inflammation, and ...
Jonathan Barratt, Jonathan Barratt, Ilene Weitz   +2 more
doaj   +2 more sources

Alternative Complement Pathway Inhibition Abrogates Pneumococcal Opsonophagocytosis in Vaccine-Naïve, but Not in Vaccinated Individuals [PDF]

Frontiers in Immunology, 2021
To assess the relative contribution of opsonisation by antibodies, classical and alternative complement pathways to pneumococcal phagocytosis, we analyzed killing of pneumococci by human blood leukocytes collected from vaccine-naïve and PCV13-vaccinated ...
Lukas Muri, Lukas Muri, Emma Ispasanie, Emma Ispasanie, Anna Schubart, Christine Thorburn, Natasa Zamurovic, Thomas Holbro, Michael Kammüller, Gerd Pluschke, Gerd Pluschke   +10 more
doaj   +2 more sources

Low molecular weight polysialic acid binds to properdin and reduces the activity of the alternative complement pathway [PDF]

Scientific Reports, 2022
Sialic acids as the terminal caps of the cellular glycocalyx play an essential role in self-recognition and were shown to modulate complement processes via interaction between α2,3-linked sialic acids and complement factor H. Previously, it was suggested
Anahita Shahraz, Yuchen Lin, Joshua Mbroh, Jonas Winkler, Huan Liao, Marie Lackmann, Annemarie Bungartz, Peter F. Zipfel, Christine Skerka, Harald Neumann   +9 more
doaj   +2 more sources

The Alternative Complement Pathway Is Activated Without a Corresponding Terminal Pathway Activation in Patients With Heart Failure [PDF]

Frontiers in Immunology, 2021
ObjectiveDysregulation of the complement system has been described in patients with heart failure (HF). However, data on the alternative pathway are scarce and it is unknown if levels of factor B (FB) and the C3 convertase C3bBbP are elevated in these ...
Margrethe Flesvig Holt, Margrethe Flesvig Holt, Annika E. Michelsen, Annika E. Michelsen, Negar Shahini, Elisabeth Bjørkelund, Christina Holt Bendz, Richard J. Massey, Richard J. Massey, Camilla Schjalm, Bente Halvorsen, Bente Halvorsen, Kaspar Broch, Kaspar Broch, Thor Ueland, Thor Ueland, Thor Ueland, Lars Gullestad, Lars Gullestad, Lars Gullestad, Per H. Nilsson, Per H. Nilsson, Pål Aukrust, Pål Aukrust, Pål Aukrust, Tom Eirik Mollnes, Tom Eirik Mollnes, Tom Eirik Mollnes, Tom Eirik Mollnes, Mieke C. Louwe   +29 more
doaj   +2 more sources

PolySialic Acid Nanoparticles Actuate Complement-Factor-H-Mediated Inhibition of the Alternative Complement Pathway: A Safer Potential Therapy for Age-Related Macular Degeneration [PDF]

Pharmaceuticals
The alternative pathway of the complement system is implicated in the etiology of age-related macular degeneration (AMD). Complement depletion with pegcetacoplan and avacincaptad pegol are FDA-approved treatments for geographic atrophy in AMD that, while
Sheri L. Peterson, Anitha Krishnan, Diyan Patel, Ali Khanehzar, Amit Lad, Jutamas Shaughnessy, Sanjay Ram, David Callanan, Derek Kunimoto, Mohamed A. Genead, Michael J. Tolentino   +10 more
doaj   +2 more sources

Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy [PDF]

Blood Cancer Journal, 2023
Thrombotic microangiopathy (TMA) has been reported to occur in multiple myeloma (MM) patients in association with treatment with carfilzomib, an irreversible proteasome inhibitor (PI).
Maria Moscvin, Christine Ivy Liacos, Tianzeng Chen, Foteini Theodorakakou, Despina Fotiou, Shahrier Hossain, Sean Rowell, Houry Leblebjian, Eileen Regan, Peter Czarnecki, Filippo Bagnoli, Niccolo’ Bolli, Paul Richardson, Helmut G. Rennke, Meletios A. Dimopoulos, Efstathios Kastritis, Giada Bianchi   +16 more
doaj   +2 more sources

Quantitative Modeling of the Alternative Pathway of the Complement System. [PDF]

PLoS ONE, 2016
The complement system is an integral part of innate immunity that detects and eliminates invading pathogens through a cascade of reactions. The destructive effects of the complement activation on host cells are inhibited through versatile regulators that
Nehemiah Zewde, Ronald D Gorham, Angel Dorado, Dimitrios Morikis   +3 more
doaj   +7 more sources

Alternative Complement Pathway in Carotid Atherosclerosis: Low Plasma Properdin Levels Associate With Long‐Term Cardiovascular Mortality [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Complement activation may promote atherosclerosis. Yet, data on the to which extent complement, and more specifically the alternative complement pathway, is activated in patients with carotid atherosclerosis and related to adverse outcome in ...
Mieke C. Louwe, Chrysostomi Gialeli, Annika E. Michelsen, Sverre Holm, Andreas Edsfeldt, Karolina Skagen, Tove Lekva, Maria Belland Olsen, Vigdis Bjerkeli, Therese Schjørlien, Kristine Stø, Xiang Yi Kong, Tuva B. Dahl, Per H. Nilsson, Peter Libby, Pål Aukrust, Tom Eirik Mollnes, Thor Ueland, Mona Skjelland, Isabel Gonçalves, Bente Halvorsen   +20 more
doaj   +2 more sources

Complement 1 Inhibitor Is a Regulator of the Alternative Complement Pathway [PDF]

The Journal of Experimental Medicine, 2001
We studied complement 1 inhibitor (C1-INH) as an inhibitor of the alternative complement pathway. C1-INH prevented lysis, induced by the alternative complement pathway, of paroxysmal nocturnal hemoglobinuria (PNH) erythrocytes in human serum. It inhibited the binding of both factors B and C3 to PNH and rabbit erythrocytes and blocked the ability of ...
Haixiang Jiang, Éric Wagner, Huamei Zhang, Michael M. Frank   +3 more
openalex   +5 more sources